SE

Martin Malmsten


Average Co-Inventor Count = 1.0

ph-index = 1


Loading Chart...

Title: Martin Malmsten: Innovator in Pharmaceutical Nanoparticle Technology

Introduction

Martin Malmsten is a notable inventor based in Sweden, recognized for his contributions to the field of pharmaceutical compositions. His work primarily focuses on methods for producing stable, amorphous hybrid nanoparticles that are essential for delivering poorly water-soluble drugs. Despite having no patents registered under his name, his innovative ideas have the potential to significantly impact the pharmaceutical industry.

Latest Patents

Malmsten's latest patents include:

1. A Method For Producing Stable, Amorphous Hybrid Nanoparticles Comprising At Least One Protein Kinase Inhibitor And At Least One Polymeric Stabilizing And Matrix-Forming Component. This invention relates to methods for providing components of pharmaceutical compositions that include poorly water-soluble drugs.

2. A Pharmaceutical Composition Comprising Stable, Amorphous Hybrid Nanoparticles Of At Least One Protein Kinase Inhibitor And At Least One Polymeric Stabilizing And Matrix-Forming Component. This patent focuses on pharmaceutical compositions that utilize stable, amorphous hybrid nanoparticles for therapeutic applications.

Career Highlights

Throughout his career, Martin Malmsten has worked with several companies, including Xspray Microparticles AB and Pergamum AB. His experience in these organizations has allowed him to develop and refine his innovative approaches to pharmaceutical technology.

Collaborations

Malmsten has collaborated with notable professionals in his field, including Magnus Brisander and Mustafa Demirbuker. These collaborations have contributed to the advancement of his research and the development of new pharmaceutical solutions.

Conclusion

Martin Malmsten is a significant figure in the realm of pharmaceutical innovations, particularly in the development of hybrid nanoparticles for drug delivery. His work continues to pave the way for advancements in the treatment of poorly water-soluble drugs.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…